Format

Send to

Choose Destination
ACS Chem Biol. 2013 Aug 16;8(8):1747-54. doi: 10.1021/cb3006165. Epub 2013 Jun 10.

A small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK kinases.

Author information

1
Medicinal Chemistry, Translational Research Institute, The Scripps Research Institute, Jupiter, Florida 33458, United States. yfeng@scripps.edu

Abstract

Both JNK and LRRK2 are associated with Parkinson's disease (PD). Here we report a reasonably selective and potent kinase inhibitor (compound 6) that bound to both JNK and LRRK2 (a dual inhibitor). A bidentate-binding strategy that simultaneously utilized the ATP hinge binding and a unique protein surface site outside of the ATP pocket was applied to the design and identification of this kind of inhibitor. Compound 6 was a potent JNK3 and modest LRRK2 dual inhibitor with an enzyme IC50 value of 12 nM and 99 nM (LRRK2-G2019S), respectively. Compound 6 also exhibited good cell potency, inhibited LRRK2:G2019S-induced mitochondrial dysfunction in SHSY5Y cells, and was demonstrated to be reasonably selective against a panel of 116 kinases from representative kinase families. Design of such a probe molecule may help enable testing if dual JNK and LRRK2 inhibitions have added or synergistic efficacy in protecting against neurodegeneration in PD.

PMID:
23751758
PMCID:
PMC3759981
DOI:
10.1021/cb3006165
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center